Insider Selling: Bicycle Therapeutics plc (NASDAQ:BCYC) COO Sells 4,578 Shares of Stock

Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) COO Alistair Milnes sold 4,578 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total transaction of $64,504.02. Following the completion of the transaction, the chief operating officer now owns 100,724 shares of the company's stock, valued at $1,419,201.16. This represents a 4.35 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bicycle Therapeutics Stock Performance

Shares of BCYC stock traded down $0.01 on Monday, reaching $14.88. 289,310 shares of the company's stock traded hands, compared to its average volume of 435,603. The company has a market capitalization of $1.03 billion, a P/E ratio of -4.52 and a beta of 0.92. Bicycle Therapeutics plc has a 12-month low of $12.17 and a 12-month high of $28.67. The business's 50 day moving average price is $19.27 and its two-hundred day moving average price is $21.86.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.04. The company had revenue of $2.68 million for the quarter, compared to the consensus estimate of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm's quarterly revenue was down 50.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.26) EPS. Research analysts predict that Bicycle Therapeutics plc will post -3.05 earnings per share for the current year.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCYC. Assetmark Inc. acquired a new position in shares of Bicycle Therapeutics in the third quarter worth $34,000. GAMMA Investing LLC increased its position in Bicycle Therapeutics by 105.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company's stock worth $46,000 after purchasing an additional 1,038 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company's stock worth $162,000 after purchasing an additional 2,918 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after buying an additional 1,782 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Bicycle Therapeutics in the 2nd quarter valued at approximately $206,000. Hedge funds and other institutional investors own 86.15% of the company's stock.

Wall Street Analysts Forecast Growth

BCYC has been the topic of several recent research reports. B. Riley reduced their price objective on Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating on the stock in a research report on Friday, December 13th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Stephens began coverage on Bicycle Therapeutics in a report on Friday, November 8th. They issued an "equal weight" rating and a $25.00 price target for the company. HC Wainwright decreased their target price on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a "buy" rating for the company in a research note on Monday, December 16th. Finally, Needham & Company LLC restated a "buy" rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Bicycle Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.25.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.